Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Monotherapy or Combination in Early Stage NSCLC
NCT04015778Phase 2Active, not recruiting
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Aug 2019
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Guangdong Association of Clinical Trials. Started Aug 2019; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04015778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04015778.